Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
about
Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC)Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's diseaseCulture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileumMultidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs DiseaseOral budesonide for induction of remission in ulcerative colitisType I interferons for induction of remission in ulcerative colitisOral budesonide for induction of remission in ulcerative colitisOral budesonide for induction of remission in ulcerative colitisType I interferons for induction of remission in ulcerative colitisRole of the gut microbiota in defining human healthThe C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10Isotretinoin use and the risk of inflammatory bowel disease: a case-control studyVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseSynthesis and characterization of a thermally-responsive tumor necrosis factor antagonistVedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel diseaseIntestinal inflammation and the diet: Is food friend or foe?Advances in nutritional therapy in inflammatory bowel diseases: ReviewMitochondrial dysfunction in inflammatory bowel diseaseEvaluating the Oxidative Stress in Inflammation: Role of MelatoninEpidemiology of intrafamilial inflammatory bowel disease throughout EuropeThe CB2 receptor and its role as a regulator of inflammationThe changing microbial landscape of Western society: Diet, dwellings and discordanceThe flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective moleculesPreventive and therapeutic euphol treatment attenuates experimental colitis in micePeptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gammaLoss of estrogen-mediated immunoprotection underlies female gender bias in experimental Crohn's-like ileitis.A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyThe transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitisThe NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variantsInflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003).Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease.Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding studySelective targeting of nanocarriers to neutrophils and monocytes.Review article: diet and inflammatory bowel disease--epidemiology and treatment.TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells.Influence of smoking on colonic gene expression profile in Crohn's disease.Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel diseaseProtectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection.Epidemiology of pediatric inflammatory bowel diseases in southern iran
P2860
Q21263046-8899C5C9-4F9E-493E-A3DE-D916CE597454Q21560778-C005A42B-82D5-4581-BB83-E27D9B115322Q22251107-E49AA5CA-A6B1-4C1C-A93D-A32BBD85415EQ22252899-6D638B79-2AF5-48D2-A19A-81595D07265FQ24186368-C64C55E7-32FE-43A0-B1A9-625A822E49FEQ24187202-6BAC96A3-3022-487D-8D0F-A2676FCBC4B8Q24234633-D94A5F47-FEAC-415B-AA94-3FEDF101CBCCQ24240602-C0C981D2-148C-4CAB-8C66-F2D44D8F92B2Q24241993-7FFA7491-2631-40EC-946F-07FDE96F3862Q24599062-2B6A2F89-C326-42A1-9AAE-4DB3056F85C1Q24620635-3218A604-72D0-4DDA-9050-67B6D08E8FAEQ24621195-8A9FE4EC-C022-41AA-A2E8-15A80DD079BBQ24630083-93C1D008-07AD-45CC-AFF1-19E13F672CB0Q24656182-141E64A7-5A42-4BD1-9B0E-744836602447Q26752768-E98C0213-54FA-4BF8-AD03-2DEC03BF30B8Q26765223-F2D7FFB9-C1E4-4DE0-AE28-C75733973CA7Q26774563-A32E8EB3-95B5-4A75-AF26-F1CD8BC3D526Q26781311-615E424D-0629-4C08-9199-1B961B960F2DQ26801531-0D77BCD4-3F56-4F48-9B71-9608E8F01BF2Q26999295-CCC893B3-C094-4FCF-8634-FE720EC7367AQ28066700-42725C61-3BB9-4B0B-AC71-743897395544Q28077979-B23A55B2-EE1A-432A-A5D2-E41635A1B269Q28469238-B1A09222-0200-4065-9001-E8B79DBDF3A7Q28477758-DD042798-2496-4AB0-B200-CB5571D22ABFQ28587904-F66A941A-2421-4C0B-BE1E-E9C2B066607BQ30407800-709572B1-24E5-4B05-B013-A5E1188DEB67Q30430605-B11A6074-545D-4EE8-B9B4-A6AAD4F41866Q30483252-B2361C39-F7DA-4671-A497-D99202D80852Q30994539-73D3BB01-E75D-40F2-895B-A0E3C13514A7Q31157440-F19200DD-0460-4E95-AB0C-AD14394B795BQ33270858-64C13FE7-9CB8-4AC1-AF92-C24B3C2BF181Q33362566-321FADA2-DC4F-48C0-9A12-67AE7B747272Q33420096-411FEAC5-5D50-4E57-8CA6-1A38CF2DA3F8Q33433964-1C7EDD6A-DA15-45C8-AF5C-9D79ACEEB3FEQ33445163-7CA70204-30EC-49E0-AB10-34B7625D26DCQ33481328-BFE8A770-542F-42D8-A65C-CA9D1D3C8BFAQ33482165-FE981F4B-FDE4-41F0-8A82-19A039039295Q33515830-E62EC137-779A-4F25-877B-B825839D743DQ33569384-0DAD5669-0050-4D3B-B7F4-20BB05830CBDQ33597346-C7AE9765-D3A5-4F9D-8CB2-E8EF27122394
P2860
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@ast
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@en
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@nl
type
label
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@ast
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@en
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@nl
prefLabel
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@ast
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@en
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@nl
P921
P1476
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
@en
P2093
Stephen B Hanauer
P356
10.1097/01.MIB.0000195385.19268.68
P478
12 Suppl 1
P577
2006-01-01T00:00:00Z